Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's (NOV: N) Wegovy (semaglutide) ...

The Danish biotech’s recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed ...

Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment. Zealand Pharma remains on track to initiate ...

Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.

“With best-in-class potential and a strong partnership agreement in place, petrelintide should be well positioned to be a leading amylin therapeutic in the next decade,” analysts led by Laura ...

“With best-in-class potential and a strong partnership agreement in place, petrelintide should be well positioned to be a leading amylin therapeutic in the next decade,” analysts led by Laura A.

The Danish biotech’s recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential to become a next-generation alternative to ...

Roche's move for the asset comes shortly after Zealand started the phase 2b ZUPREME-1 trial of petrelintide in people overweight or obese, and ahead of the ZUPREME-2 study in overweight or obese ...

The announcement comes just days after Roche entered into a partnership worth up to $5.3bn to advance Zealand Pharma’s mid-stage obesity candidate petrelintide. The exclusive collaboration and ...